BeyondSpring Inc Reports Compelling New Data on Plinabulin Advances Both the Anticancer Efficacy and Safety of Adc Drugs Apr 24
New major risk - Financial position Mar 26
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 Dec 12
Beyondspring Inc. Announces New Post-Hoc Analyses from Its Global Phase 3 Dublin-3Study Dec 11
BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $2 million. Nov 22
BeyondSpring Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Nov 18
Insufficient new directors Sep 01
BeyondSpring Inc. Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure Jul 07
BeyondSpring Inc., Annual General Meeting, Sep 15, 2025 Jul 06
New major risk - Share price stability Jun 12
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting Jun 03
New minor risk - Share price stability May 06
New major risk - Revenue size Mar 28
New minor risk - Financial data availability Mar 17
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting Nov 12
BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024 Sep 16
First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023) Sep 02
New minor risk - Shareholder dilution Sep 01
New minor risk - Market cap size Apr 09
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule Feb 28
First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022) Feb 07
New major risk - Revenue and earnings growth Dec 31
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity Nov 08
New minor risk - Financial data availability Nov 05
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement Oct 31
New major risk - Share price stability Oct 13
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Oct 05
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director Jul 15
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT Jun 08
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 19
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules Jan 10
BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023 Jan 01
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Nov 24
Price target decreased to US$2.30 Nov 16
BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 Sep 14
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index Jun 26
BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022 Jun 14
BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer Jun 10
Price target decreased to US$6.10 May 02
Consensus forecasts updated Apr 21
Price target increased to US$13.67 Apr 14
BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022 Apr 09
BeyondSpring Pharmaceuticals Announces Organizational Streamlining Jan 12
Consensus revenue estimates fall by 90% Jan 07
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition Dec 16
Consensus forecasts updated Dec 03
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN) Dec 02
No longer forecast to breakeven Nov 25
Price target decreased to US$58.60 Sep 21
Price target increased to US$67.25 Aug 05
Consensus forecasts updated Jun 30
Consensus forecasts updated Jun 23
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting Jun 11
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting Jun 09
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors Jun 05
BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia Jun 02
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting Apr 29
Chief Scientific Officer has left the company Mar 21
BeyondSpring Inc. Announces Management Changes Mar 21
Price target lowered to US$36.00 Dec 30
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors Dec 19
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium Dec 11
BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million. Nov 20
BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia Nov 17
New 90-day high: US$16.02 Nov 07
BeyondSpring Forms Partnership Advisory Committee Oct 13
New 90-day high: US$15.36 Oct 10
BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy Oct 04
BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, Plinabulin Sep 26
BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial Officer Sep 24
BeyondSpring Inc. to Report Q2, 2020 Results on Sep 03, 2020 Aug 29 
